Cargando…
Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France
Background: P. aeruginosa implant-associated bone and joint infections (BJI) is considered to be one of the most difficult to treat BJI. The data focusing specifically on this pathogen are sparse, and it seems difficult to extrapolate the results obtained with Enterobacteriaceae. Methods: We perform...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649271/ https://www.ncbi.nlm.nih.gov/pubmed/33195289 http://dx.doi.org/10.3389/fmed.2020.513242 |
_version_ | 1783607289202081792 |
---|---|
author | Cerioli, Matteo Batailler, Cécile Conrad, Anne Roux, Sandrine Perpoint, Thomas Becker, Agathe Triffault-Fillit, Claire Lustig, Sebastien Fessy, Michel-Henri Laurent, Frederic Valour, Florent Chidiac, Christian Ferry, Tristan |
author_facet | Cerioli, Matteo Batailler, Cécile Conrad, Anne Roux, Sandrine Perpoint, Thomas Becker, Agathe Triffault-Fillit, Claire Lustig, Sebastien Fessy, Michel-Henri Laurent, Frederic Valour, Florent Chidiac, Christian Ferry, Tristan |
author_sort | Cerioli, Matteo |
collection | PubMed |
description | Background: P. aeruginosa implant-associated bone and joint infections (BJI) is considered to be one of the most difficult to treat BJI. The data focusing specifically on this pathogen are sparse, and it seems difficult to extrapolate the results obtained with Enterobacteriaceae. Methods: We performed a retrospective observation study of all P. aeruginosa implant-associated BJI diagnosed at our institution from 2011 to 2018. We defined failure as any type of relapse, including persistence of the same P. aeruginosa, superinfection by another organism(s) or any other cause of relapse such as the need for a subsequent surgery. Nonparametric statistical methods were used to compare the study groups and Kaplan-Meier curves and multivariate Cox analysis and were used to detect determinants associated with treatment failure. Results: A total of 90 patients (62% men, median age 60 years IQR 47–72) including 30 (33%) prosthetic-joint infections and 60 (66%) other implant-associated BJIs were studied. Most of them were acute (62%). During the prolonged follow-up, (median 20 months; IQR 9–37), 23 patients (26%) experienced treatment failure. Optimal surgical treatment (DAIR for acute forms, explantation, 1-stage or 2-stage exchange for others) was significantly associated with a higher success rate in the univariate analysis (p = 0.003). Sixty-four (71%) patients received effective initial treatment against P. aeruginosa administered and 81 of them (90%) did for at least 3 weeks: both these parameters correlated with a higher success rate. In the multivariate Cox-analysis optimal surgical treatment, IV effective treatment of at least 3 weeks and treatment with ciprofloxacin for at least 3 months proved to be independently associated to a better outcome in patients with P. aeruginosa implant-associated BJI. Conclusion: P. aeruginosa implant-associated BJI is one of the most difficult-to-treat BJI, with a strong impact on the prognosis of the surgical strategy. An effective initial IV antibiotic treatment for at least 3 weeks seems to be required, followed by oral ciprofloxacin for a total duration of 3 months. |
format | Online Article Text |
id | pubmed-7649271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76492712020-11-13 Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France Cerioli, Matteo Batailler, Cécile Conrad, Anne Roux, Sandrine Perpoint, Thomas Becker, Agathe Triffault-Fillit, Claire Lustig, Sebastien Fessy, Michel-Henri Laurent, Frederic Valour, Florent Chidiac, Christian Ferry, Tristan Front Med (Lausanne) Medicine Background: P. aeruginosa implant-associated bone and joint infections (BJI) is considered to be one of the most difficult to treat BJI. The data focusing specifically on this pathogen are sparse, and it seems difficult to extrapolate the results obtained with Enterobacteriaceae. Methods: We performed a retrospective observation study of all P. aeruginosa implant-associated BJI diagnosed at our institution from 2011 to 2018. We defined failure as any type of relapse, including persistence of the same P. aeruginosa, superinfection by another organism(s) or any other cause of relapse such as the need for a subsequent surgery. Nonparametric statistical methods were used to compare the study groups and Kaplan-Meier curves and multivariate Cox analysis and were used to detect determinants associated with treatment failure. Results: A total of 90 patients (62% men, median age 60 years IQR 47–72) including 30 (33%) prosthetic-joint infections and 60 (66%) other implant-associated BJIs were studied. Most of them were acute (62%). During the prolonged follow-up, (median 20 months; IQR 9–37), 23 patients (26%) experienced treatment failure. Optimal surgical treatment (DAIR for acute forms, explantation, 1-stage or 2-stage exchange for others) was significantly associated with a higher success rate in the univariate analysis (p = 0.003). Sixty-four (71%) patients received effective initial treatment against P. aeruginosa administered and 81 of them (90%) did for at least 3 weeks: both these parameters correlated with a higher success rate. In the multivariate Cox-analysis optimal surgical treatment, IV effective treatment of at least 3 weeks and treatment with ciprofloxacin for at least 3 months proved to be independently associated to a better outcome in patients with P. aeruginosa implant-associated BJI. Conclusion: P. aeruginosa implant-associated BJI is one of the most difficult-to-treat BJI, with a strong impact on the prognosis of the surgical strategy. An effective initial IV antibiotic treatment for at least 3 weeks seems to be required, followed by oral ciprofloxacin for a total duration of 3 months. Frontiers Media S.A. 2020-10-26 /pmc/articles/PMC7649271/ /pubmed/33195289 http://dx.doi.org/10.3389/fmed.2020.513242 Text en Copyright © 2020 Cerioli, Batailler, Conrad, Roux, Perpoint, Becker, Triffault-Fillit, Lustig, Fessy, Laurent, Valour, Chidiac, Ferry. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Cerioli, Matteo Batailler, Cécile Conrad, Anne Roux, Sandrine Perpoint, Thomas Becker, Agathe Triffault-Fillit, Claire Lustig, Sebastien Fessy, Michel-Henri Laurent, Frederic Valour, Florent Chidiac, Christian Ferry, Tristan Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France |
title | Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France |
title_full | Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France |
title_fullStr | Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France |
title_full_unstemmed | Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France |
title_short | Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France |
title_sort | pseudomonas aeruginosa implant-associated bone and joint infections: experience in a regional reference center in france |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649271/ https://www.ncbi.nlm.nih.gov/pubmed/33195289 http://dx.doi.org/10.3389/fmed.2020.513242 |
work_keys_str_mv | AT ceriolimatteo pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT bataillercecile pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT conradanne pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT rouxsandrine pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT perpointthomas pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT beckeragathe pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT triffaultfillitclaire pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT lustigsebastien pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT fessymichelhenri pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT laurentfrederic pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT valourflorent pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT chidiacchristian pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance AT ferrytristan pseudomonasaeruginosaimplantassociatedboneandjointinfectionsexperienceinaregionalreferencecenterinfrance |